CCS
CALA

Crosspoint Capital Strategies’s Calithera Biosciences, Inc CALA Stock Holding History

Crosspoint Capital Strategies’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-25
Closed -$7K – 179
2017
Q2 		$7K Buy
+25
New +$6.69K 0.01% 95

Other funds holding CALA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Crosspoint Capital Strategies's CALA Position: Q3 2017 in Review

Crosspoint Capital Strategies sold out of Calithera Biosciences, Inc (CALA) in Q3 2017, closing a stake of 25 shares — an estimated $7K sold.

Crosspoint Capital Strategies first reported a position in CALA in Q2 2017 and held it in 1 quarter. The position peaked at $7K in Q2 2017. 91 funds tracked by Wall St. Rank hold CALA as of Q3 2017.

  • Crosspoint Capital Strategies reported no remaining Calithera Biosciences, Inc position as of Q3 2017 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 25 Calithera Biosciences, Inc shares in Q3 2017, an estimated $7K.
  • Crosspoint Capital Strategies first reported a position in Calithera Biosciences, Inc in Q2 2017 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Calithera Biosciences, Inc position peaked at $7K in Q2 2017.
  • 91 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2017.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2017, filed 6 Nov 2017.